tickrz reports
  
tickrz rank
D
Edwards Lifesciences Corp (EW)
Healthcare | Medical Appliances & Equipment
CEO: Michael A. Mussallem
Employees: 9800
edwards.com
FACTOR RANKINGSFACTOR SCREENER 
Pure Value Rank457Dividend RankNO DIVIDEND
Moat Rank51Financial Strength Rank7
Growth Rank29Momentum Rank404
DIVIDEND ANALYSIS
Dividend Yield0%
Payout RatioN/A
3 yr Dividend GrowthN/A
VALUATION RATIOS
P/E Ratio37.2x
P/B Ratio8.91x
P/S Ratio7.76x
EV/EBITDA Ratio25.55x
FINANCIAL STRENGTH
Piotroski F-Score7
Debt-to-Equity31%
Interest Coverage44.61x
MOAT
ROE26.05%
ROIC35.66%
Net Margin19.22%
GROWTH
5 yr EPS Growth21.4%
5 yr SPS Growth12.04%
5 yr BPS Growth16.12%
Edwards Lifesciences Corp 's strong growth translates to a Growth Rank in the top 25% of all stocks
 tickrz summary
Edwards Lifesciences Corp receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
 value
 pure value ranking Warren Buffett ranking
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Edwards Lifesciences Corp's valuation score is comprised of a P/E ratio of 37.2x, a P/B ratio of 8.9x, a P/S ratio of 7.8x, and an EV/EBITDA ratio of 25.6x. Edwards Lifesciences Corp ranks 457 out of the S&P 500 constituents on valuation--a relatively weak score.Edwards Lifesciences Corp ranks 251 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Edwards Lifesciences Corp is probably not for you. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.

 quality
 moat financial strength
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Edwards Lifesciences Corp appears to have a durable competitive advantage within the Healthcare sector. Edwards Lifesciences Corp has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 44.61x, a debt/equity ratio of 31% and a Moat Rank of 51 translate to a strong Financial Strength score.


 momentum
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -1.16% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 404. Based on its 12 month stock performance, Edwards Lifesciences Corp will not appeal to momentum investors.

 yield
 value + yield
Edwards Lifesciences Corp currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

 growth
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 21.4% 5 year annualized EPS growth, 12% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 16.1% speak to its impressive growth ranking.

Edwards Lifesciences Corp (EW)
Healthcare | Medical Appliances & Equipment
CEO: Michael A. Mussallem
Employees: 9800
edwards.com


tickrz rank
D

VALUATION RATIOS
P/E Ratio37.2x
P/B Ratio8.91x
P/S Ratio7.76x
EV/EBITDA Ratio25.55x
DIVIDEND ANALYSIS
Dividend Yield0%
Payout RatioN/A
3 yr Dividend GrowthN/A
FINANCIAL STRENGTH
Piotroski F-Score7
Debt-to-Equity31%
Interest Coverage44.61x
MOAT
ROE26.05%
ROIC35.66%
Net Margin19.22%
GROWTH
5 yr EPS Growth21.4%
5 yr SPS Growth12.04%
5 yr BPS Growth16.12%

TICKRZ RANK
Edwards Lifesciences Corp receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Edwards Lifesciences Corp's valuation score is comprised of a P/E ratio of 37.2x, a P/B ratio of 8.9x, a P/S ratio of 7.8x, and an EV/EBITDA ratio of 25.6x. Edwards Lifesciences Corp ranks 457 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Edwards Lifesciences Corp ranks 251 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Edwards Lifesciences Corp is probably not for you. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Edwards Lifesciences Corp appears to have a durable competitive advantage within the Healthcare sector.

FINANCIAL STRENGTH
Edwards Lifesciences Corp has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 44.61x, a debt/equity ratio of 31% and a Moat Rank of 51 translate to a strong Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -1.16% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 404. Based on its 12 month stock performance, Edwards Lifesciences Corp will not appeal to momentum investors.

VALUE + YIELD
Edwards Lifesciences Corp currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 21.4% 5 year annualized EPS growth, 12% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 16.1% speak to its impressive growth ranking.